Candel Therapeutics GAAP EPS of -$0.54
Source: SeekingAlpha
2026-03-12 15:02:57 ET
More on Candel Therapeutics
- Candel Therapeutics launches $100M public stock offering; shares down
- Seeking Alpha’s Quant Rating on Candel Therapeutics
- Historical earnings data for Candel Therapeutics
- Financial information for Candel Therapeutics
Read the full article on Seeking Alpha
For further details see:
Candel Therapeutics GAAP EPS of -$0.54
Candel Therapeutics Inc.
NASDAQ: CADL
CADL Trading
-4.43% G/L:
$4.745 Last:
703,959 Volume:
$5.04 Open:
CADL Latest News
March 12, 2026 08:05:00 am
Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
March 09, 2026 08:05:00 am
Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
February 24, 2026 08:05:00 am
Candel Therapeutics to Present at TD Cowen's 46th Annual Health Care Conference in Boston
CADL Stock Data
$316,763,208
45,785,185
2.24%
22
N/A
Biotechnology & Life Sciences
Healthcare
US
Needham
